When MorphoSys acquired Cambridge, Massachusetts-based Constellation Pharmaceuticals last year, the $1.7 billion deal value represented the entirety of the cancer drug developer’s pipeline ...

Four bright stars outline the package, while three others make up the decorative bow. [Stunning Night Sky Photos of December 2012] ... within the faint zodiacal constellation of Cancer. ...

Constellation Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 PROSTAR Combination Study of CPI-1205 in Advanced Form of Prostate Cancer First solid tumor study from company’s EZH2 ...

MorphoSys is acquiring Constellation Pharmaceuticals and its late-stage myelofibrosis drug in a deal that values the epigenetics biotech at $1.7 billion. Germany-based MorphoSys will finance the ...

Constellation Pharmaceuticals, which is developing epigenetic cancer therapies that modulate abnormal genes, announced terms for its IPO on Monday. The Cambridge, MA-based company plans to raise ...